Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. (ARQT) Revenue
Annual & quarterly revenue history · segment & region breakdown
ARQT · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsArcutis Biotherapeutics, Inc. trailing twelve-month (TTM) revenue is $0.42B, an increase of 91.34% year-over-year from $0.38B in FY2025.
Revenue trend
2025 – 2017 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.38B | +$0.18B | +91.34% |
| 2024-12-31 | $0.20B | +$0.14B | +229.74% |
| 2023-12-31 | $0.06B | +$0.06B | +1517.09% |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare ARQT revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Arcutis Biotherapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Arcutis Biotherapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Arcutis Biotherapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ARQT revenue · 4 questionsARQT's trailing twelve-month (TTM) revenue is $0.42B. That is an increase of 91.34% year-over-year from $0.38B in FY2025.
▸ Source: FMP · Arcutis Biotherapeutics, Inc. SEC filings · GAAP · Arcutis Biotherapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026